Role of Blepharoexfoliation in Demodex Blepharitis: A Randomized Comparative Study.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
received:
24
09
2021
accepted:
07
03
2022
pubmed:
20
4
2022
medline:
7
12
2022
entrez:
19
4
2022
Statut:
ppublish
Résumé
The purpose of this study was to evaluate the safety and efficacy of blepharoexfoliation in the treatment of Demodex blepharitis. Patients with microscopically approved Demodex blepharitis were enrolled. Patients in the treatment group were treated once with in-office blepharoexfoliation (BlephEx LLC; Franklin, TN) using tea tree oil 2% shampoo, followed by eyelid scrubs with tea tree oil 2% shampoo twice a day for 8 weeks. Patients in the control group were treated with the same protocol, except for the in-office sham blepharoexfoliation procedure. As the main outcome measurement, the changes in the severity of symptoms [Ocular Surface Disease Index (OSDI) score] were compared. The changes in Demodex count and meibomian gland dysfunction (MGD) severity were compared as the secondary outcome measurements. Eighty-one patients (36 male and 45 female) were included. The mean age of the patients was 53.56 ± 8.13 years. The mean baseline OSDI score was 33.30 ± 11.80. The mean baseline Demodex count was 4.84 ± 1.49. The Demodex count at the baseline visit was moderately correlated with the baseline OSDI score (R = 0.526, P = 0.011) and baseline MGD severity ( P = 0.02). At the 8-week visit, the OSDI score was 22.62 ± 8.23 and 27.09 ± 9.11 in the blepharoexfoliation and control groups, respectively ( P = 0.016). At the 8-week visit, the Demodex count was 2.6 ± 1.08 and 3.03 ± 1.27 in the treatment and control groups, respectively ( P = 0.025). MGD improved in both groups ( P = 0.84). In the blepharoexfoliation group, the change in the OSDI score was moderately correlated with the baseline OSDI score (R = 0.611, P = 0.01). One session of blepharoexfoliation, followed by manual eyelid scrubs was more effective than eyelid scrubs alone in reducing patients' symptoms and Demodex count.
Identifiants
pubmed: 35439775
doi: 10.1097/ICO.0000000000003046
pii: 00003226-202301000-00007
doi:
Substances chimiques
Tea Tree Oil
68647-73-4
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-51Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest statement: The authors have no funding or conflicts of interest to disclose.
Références
Rusiecka-Ziółkowska J, Nokiel M, Fleischer M. Demodex—an old pathogen or a new one?. Adv Clin Exp Med. 2014;23:295–298.
Zhang XB, Ding YH, He W. The association between demodex infestation and ocular surface manifestations in meibomian gland dysfunction. Int J Ophthalmol. 2018;11:589–592.
Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010;10:505–510.
Navel V, Mulliez A, Benoist d'Azy C, et al. Efficacy of treatments for Demodex blepharitis: a systematic review and meta-analysis. Ocul Surf. 2019;17:655–669.
Gao YY, Di Pascuale MA, Elizondo A, et al. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea. 2007;26:136–143.
Fulk GW, Murphy B, Robins MD. Pilocarpine gel for the treatment of demodicosis--a case series. Optom Vis Sci. 1996;73:742–745.
Holzchuh FG, Hida RY, Moscovici BK, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol. 2011;151:1030–1034.e1.
Fromstein SR, Harthan JS, Patel J, et al. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57–63.
Pakdel F, Gohari MR, Jazayeri AS, et al. Validation of farsi translation of the ocular surface disease index. J Ophthalmic Vis Res. 2017;12:301–304.
Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol (Chicago, IL). 2000;118:615–621.
Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922–1929.
Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46:3089–3094.
English FP, Nutting WB. Demodicosis of ophthalmic concern. Am J Ophthalmol. 1981;91:362–372.
English FP, Iwamoto T, Darrell RW, et al. The vector potential of Demodex folliculorum. Arch Ophthalmol (Chicago, IL). 1970;84:83–85.
Hom MM, Mastrota KM, Schachter SE. Demodex Optom Vis Sci. 2013;90:e198–e205.
Luo X, Li J, Chen C, et al. Ocular demodicosis as a potential cause of ocular surface inflammation. Cornea. 2017;36(suppl 1):S9–S14.
Murphy O, O'Dwyer V, Lloyd-McKernan A. The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. Cont Lens Anterior Eye. 2018;41:77–82.
Murphy O, Oʼ Dwyer V, Lloyd-McKernan A. The clinical use of eyelash manipulation in the diagnosis of demodex folliculorum blepharitis. Eye Contact Lens. 2020;46(suppl 1):S33–S38.
Lee SH, Chun YS, Kim JH, et al. The relationship between demodex and ocular discomfort. Invest Ophthalmol Vis Sci. 2010;51:2906–2911.
Liang L, Liu Y, Ding X, et al. Significant correlation between meibomian gland dysfunction and keratitis in young patients with Demodex brevis infestation. Br J Ophthalmol. 2018;102:1098–1102.
Yam JC, Tang BS, Chan TM, et al. Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol. 2014;24:159–163.
Kheirkhah A, Casas V, Li W, et al. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol. 2007;143:743–749.
Kim JT, Lee SH, Chun YS, et al. Tear cytokines and chemokines in patients with Demodex blepharitis. Cytokine. 2011;53:94–99.
Cheng S, Zhang M, Chen H, et al. The correlation between the microstructure of meibomian glands and ocular Demodex infestation: a retrospective case-control study in a Chinese population. Medicine (Baltimore). 2019;98:e15595.
Zarei-Ghanavati S, Jabbari Nooghabi M, Zamani G. Comparison of the effect of Tea tree oil shampoo with regular-lid shampoo in meibomian gland dysfunction treatment. Am J Ophthalmol. 2021;229:45–51.
Messager S, Hammer KA, Carson CF, et al. Assessment of the antibacterial activity of tea tree oil using the European EN 1276 and EN 12054 standard suspension tests. J Hosp Infect. 2005;59:113–125.
Oliva B, Piccirilli E, Ceddia T, et al. Antimycotic activity of Melaleuca alternifolia essential oil and its major components. Lett Appl Microbiol. 2003;37:185–187.
Koo H, Kim TH, Kim KW, et al. Ocular surface discomfort and Demodex: effect of tea tree oil eyelid scrub in Demodex blepharitis. J Korean Med Sci. 2012;27:1574–1579.
Gao YY, Di Pascuale MA, Li W, et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol. 2005;89:1468–1473.
Luo Y, Sun YJ, Zhang L, et al. Treatment of mites folliculitis with an ornidazole-based sequential therapy: a randomized trial. Medicine (Baltimore). 2016;95:e4173.
Lacey N, Kavanagh K, Tseng SC. Under the lash: demodex mites in human diseases. Biochem (Lond). 2009;31:2–6.
Epstein IJ, Rosenberg E, Stuber R, et al. Double-masked and unmasked prospective study of terpinen-4-ol lid scrubs with microblepharoexfoliation for the treatment of demodex blepharitis. Cornea. 2020;39:408–416.
Rather PA, Hassan I. Human demodex mite: the versatile mite of dermatological importance. Indian J Dermatol. 2014;59:60–66.
Moon SY, Han SA, Kwon HJ, et al. Effects of lid debris debridement combined with meibomian gland expression on the ocular surface MMP-9 levels and clinical outcomes in moderate and severe meibomian gland dysfunction. BMC Ophthalmol. 2021;21:175.